A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.
Adult
Aged
Aged, 80 and over
Female
Humans
Imatinib Mesylate
/ administration & dosage
Leukemia, Myeloid, Acute
/ drug therapy
Maintenance Chemotherapy
/ methods
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Progression-Free Survival
Protein Kinase Inhibitors
/ administration & dosage
Proto-Oncogene Proteins c-kit
/ antagonists & inhibitors
Young Adult
AF1q
CD117
Prognosis
Survival
Targeted
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
05
10
2020
revised:
24
11
2020
accepted:
25
11
2020
pubmed:
11
1
2021
medline:
18
12
2021
entrez:
10
1
2021
Statut:
ppublish
Résumé
Adults with acute myeloid leukemia (AML) have a high rate of remission; however, more than 50% relapse. C-kit is expressed in approximately 60% of patients with de novo AML and represents a potential therapeutic target. Patients with newly diagnosed AML received 12 months of imatinib mesylate as maintenance therapy after the completion of post-remission therapy. The primary objective was to determine whether this approach improved progression-free survival (defined as no relapse and no death) compared with historical controls. The median progression-free survival of patients < 60 years of age was 52.1 months (historical control, 13 months) and for patients ≥ 60 years of age was 10.7 months (historical control, 8 months). The median level of AF1q expression was high (9.59), and 84% of patients had moderate or high levels of drug-resistance factors. Imatinib maintenance therapy may improve the outcome of newly diagnosed patients with AML who are < 60 years of age.
Identifiants
pubmed: 33422470
pii: S2152-2650(20)30660-1
doi: 10.1016/j.clml.2020.11.018
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
KIT protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-118Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.